Advertisement


Egbert F. Smit, MD, PhD, on NSCLC: Treatment With Fam-trastuzumab Deruxtecan

ASCO20 Virtual Scientific Program

Advertisement

Egbert F. Smit, MD, PhD, of the Netherlands Cancer Institute, discusses interim results from the DESTINY-Lung01 trial of fam-trastuzumab deruxtecan in patients with HER2-mutated metastatic non–small cell lung cancer. The data show clinical activity with high overall response rates and durable responses (Abstract 9504).



Related Videos

Howard A. Burris III, MD, FACP, FASCO, on Highlights of the ASCO20 Virtual Scientific Program

Howard A. Burris III, MD, FACP, FASCO, talks about some of the reports of research developments he is looking forward to and how future conferences could incorporate virtual presentations.

Leukemia

Farhad Ravandi-Kashani, MD, on Acute Myeloid Leukemia: AMG 330 in Patients With Relapsed or Refractory Disease

Farhad Ravandi-Kashani, MD, of The University of Texas MD Anderson Cancer Center, discusses updates from a phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule. It showed early evidence of an acceptable safety profile, drug tolerability, and antileukemic activity, supporting further dose escalation in patients with acute myeloid leukemia (Abstract 7508).

Lymphoma
Immunotherapy

Lakshmi Nayak, MD, on Primary CNS Lymphoma: The Search for Optimal First-Line Treatment

Lakshmi Nayak, MD, of Dana-Farber Cancer Institute, reviews two key abstracts on newly diagnosed primary central nervous system lymphoma and treatment with whole-brain radiotherapy, methotrexate, temozolomide, rituximab, procarbazine, vincristine, and cytarabine (Abstracts 2500 and 2501).

Skin Cancer
Immunotherapy

Douglas B. Johnson, MD, on Melanoma: Clinical Trials Update on PD-1 and CTLA-4 Blockade

Douglas B. Johnson, MD, of Vanderbilt University Medical Center, discusses three important melanoma abstracts: the need for more than two doses of nivolumab plus ipilimumab in combination immunotherapy; antitumor activity for low-dose ipilimumab with pembrolizumab after disease progression on PD-1 antibodies; and ipilimumab alone or in combination with anti–PD-1 therapy for metastatic disease resistant to PD-1 monotherapy (Abstracts 10003, 10004, and 10005).

Multiple Myeloma
Immunotherapy

Sarah A. Holstein, MD, PhD, on Multiple Myeloma: Expert Perspective on Five Key ASCO20 Abstracts

Sarah A. Holstein, MD, PhD, of the University of Nebraska Medical Center, discusses top myeloma abstracts from the ASCO20 Virtual Scientific Program: the ENDURANCE trial on carfilzomib, lenalidomide, dexamethasone, and bortezomib; the STaMINA study on transplantation strategies; a first-in-human study on the novel CELMoD agent CC-92480 plus dexamethasone; the CARTITUDE-1 trial on CAR T-cell therapy; and a phase I study of teclistamab (Abstracts LBA3, 8506, 8500, 8505, and 100).

Advertisement

Advertisement




Advertisement